Lurasidone Hydrochloride

盐酸鲁拉西酮

Report date: 2026/03/19 20:00:18
NME

Base Information

Drug NameLurasidone Hydrochloride
Drug Alias Name鲁拉西酮lurasidonelurasidonalurasidonum罗舒达 +[9] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerotonin 2a (5-HT2a) receptor antagonistsSerotonin 1a (5-HT1a) receptor agonistsSerotonin 7 (5-HT7) receptor antagonists +[4] 
TargetsSerotonin 7 (5-HT7) receptorSerotonin 2a (5-HT2a) receptorSerotonin 1a (5-HT1a) receptor +[4] 
Therapy Area/IndicationsBipolar II DisorderBipolar I DisorderSchizophrenia +[11] 
Global Approved IndicationsSchizophreniaDepressive DisorderBipolar Disorder
Approved Indications in ChinaSchizophrenia
Original Approved Country/TerritoryUnited States
Original Approved Date2010/10/28
Country/TerritoryCzechiaBelgiumBulgaria +[38] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesSumitomo Dainippon
China Registration ClassN/A

Develop Information

Active CompaniesSunovion Pharmaceuticals IncSumitomo Dainippon Pharma Co LtdAziende Chimiche Riunite Angelini Francesco Spa +[4] 
Inactive CompaniesDainippon Sumitomo Pharma AmericaUniversity of California IrvineSumitomo Pharma America Inc +[14] 
Active IndicationsSchizophreniaDepressive Disorder, MajorDepressive Disorder +[4] 
Inactive IndicationsBipolar II DisorderBipolar I DisorderPsychotic Disorders +[7] 

Other Information

ATC CodeN05AE05
Related LinksWikipediaDrugBankKEGG